Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ectonucleoside triphosphate diphosphohydrolase 3 (CD39L3) is an ectonucleotidase that hydrolyzes extracellular nucleotides, particularly ATP and ADP, regulating purinergic signaling. It is involved in various physiological processes, including feeding and sleep regulation in the brain. CD39L3 is highly expressed in the brain, pancreas, spleen, and prostate. Alterations in CD39L3 expression have been observed in Crohn's disease patients, suggesting a potential role in inflammatory bowel diseases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ectonucleoside triphosphate diphosphohydrolase 3 (CD39L3).